The U.S. Food and Drug Administration (FDA) on Friday issued a Complete Response Letter (CRL) to Pharming Group’s (NASDAQ:PHAR) supplemental New Drug Application (sNDA) for Joenja (leniolisib) for chi[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.
